eli lilly’s novel treatment for diabetes and obesity could become one of history’s bestselling drugs bringing higher sales than wall street expects according to ubs analyst colin bristow raised his rating on eli lilly stock ticker lly to buy from neutral the drug tirzepatide marketed as mounjaro by eli lilly got regulatory approval as a diabetes treatment in may approval to use it as a weightloss remedy is still in the works but bristow thinks wall street’s estimates for potential sales are out of date and fail to recognize the size of the opportunity